UBC23 Antibody

What are the key characteristics of UBE2N/Ubc13 antibodies used in research?

UBE2N/Ubc13 antibodies such as #4919 are primarily used for Western Blotting applications at a recommended dilution of 1:1000. These antibodies typically detect endogenous levels of UBE2N/Ubc13 protein, which has a molecular weight of approximately 16 kDa. They are raised in rabbits and show cross-reactivity with human, mouse, rat, and monkey species, making them versatile tools for comparative studies across different mammalian models .

The antibody specificity is critical for accurate detection of UBE2N/Ubc13 in complex biological samples. When selecting an antibody, researchers should verify both the reactivity with their species of interest and the sensitivity for detecting endogenous protein levels rather than just overexpressed proteins.

How does UBC3 antibody compare to UBE2N/Ubc13 antibody in research applications?

While both are ubiquitin-conjugating enzyme antibodies, UBC3 antibody (#4997) differs from UBE2N/Ubc13 antibody in several important aspects:

This comparison highlights that while both antibodies share similar applications and source animals, they detect different target proteins with distinct molecular weights and slightly different species cross-reactivity profiles .

What are the appropriate storage and handling conditions for maintaining antibody integrity?

Proper storage and handling of UBE2N/Ubc13 and UBC3 antibodies are essential for maintaining their specificity and sensitivity. While specific storage information is not detailed in the search results, the following general guidelines apply to research antibodies:

• Store antibodies at the recommended temperature (typically -20°C for long-term storage)

• Avoid repeated freeze-thaw cycles by preparing working aliquots

• Store working dilutions at 4°C for short-term use

• Protect antibodies from contamination by using sterile technique

• Follow manufacturer's recommendations for adding preservatives to working dilutions

These practices help preserve antibody function across multiple experiments and extend the usable lifetime of the reagent.

How should I design experiments to investigate Ubc13's role in DNA damage response pathways?

When designing experiments to study Ubc13's role in DNA damage response (DDR), consider the following methodological approach:

• Use both genetic and chemical inhibition approaches in parallel:

  • Generate Ubc13 knockout cell lines (e.g., using CRISPR-Cas9)

  • Use Ubc13-specific inhibitors like NSC697923 at concentrations starting at 1 μM

  • Include rescue experiments with wild-type and inhibitor-resistant Ubc13 variants

• Assess DNA damage markers before and after treatment with DNA-damaging agents:

  • Monitor formation of DNA damage foci (γH2AX, 53BP1)

  • Measure recruitment of repair factors to damaged DNA sites

  • Evaluate cell cycle checkpoints and apoptosis markers

• For more definitive studies, develop inhibitor-resistant Ubc13 mutants (such as the QD mutant described in the literature) that can build Lys63-linked polyubiquitin chains but resist inhibition by compounds like NSC697923 .

This comprehensive approach allows researchers to distinguish between Ubc13-specific effects and off-target effects of chemical inhibitors in DNA damage signaling pathways.

What controls are essential when studying Ubc13 inhibition with compounds like NSC697923?

When studying Ubc13 inhibition with compounds like NSC697923, implement these critical controls:

• Include a dose-response curve of inhibitor concentrations (e.g., 0.1-10 μM NSC697923) to determine the minimum effective concentration

• Use multiple time points to distinguish between acute and delayed inhibition effects

• Compare results with both positive and negative controls:

  • Positive control: Known Ubc13-dependent processes (e.g., Lys63-linked polyubiquitination)

  • Negative control: Processes not dependent on Ubc13 function

• Include an inhibitor-resistant Ubc13 mutant as described in the literature (e.g., Ubc13 QD mutant)

• Verify inhibitor specificity by:

  • Testing the inhibitor against related E2 enzymes

  • Performing in vitro ubiquitination assays with purified components

  • Comparing cellular phenotypes between inhibitor-treated and Ubc13 knockout cells

These controls help establish whether observed effects are due to specific Ubc13 inhibition rather than off-target effects of the compounds.

How can I effectively study the differential roles of Ubc13 in nuclear versus cytoplasmic signaling?

To study Ubc13's differential roles in nuclear DNA damage signaling versus cytoplasmic NF-κB signaling:

• Generate cell compartment-specific Ubc13 variants:

  • Create nuclear localization signal (NLS)-tagged and nuclear export signal (NES)-tagged Ubc13 constructs

  • Verify localization by immunofluorescence microscopy

• Design pathway-specific activation protocols:

  • For DNA damage pathway: Use genotoxic agents (e.g., ionizing radiation, etoposide)

  • For NF-κB pathway: Use specific activators like LPS, TNF-α, or IL-1β

• Measure pathway-specific readouts:

  • DNA damage: γH2AX foci formation, comet assay, 53BP1 recruitment

  • NF-κB activation: Nuclear translocation of p65, IκB degradation, target gene expression, cytokine release profiles

• Use inhibitor studies with complementary approaches:

  • Compare NSC697923 and BAY 11-7082 effects on both pathways

  • Include the Ubc13 QD mutant (resistant to NSC697923) to validate pathway-specific observations

This integrated approach enables researchers to dissect the compartment-specific functions of Ubc13 in various signaling cascades.

What are the optimal conditions for detecting Ubc13-mediated polyubiquitination in cell-free systems?

For optimal detection of Ubc13-mediated polyubiquitination in cell-free systems:

• Assemble reaction components in the following stoichiometry:

  • E1 (ubiquitin-activating enzyme): 50-100 nM

  • Ubc13: 500 nM to 1 μM

  • Mms2 (Ubc13 cofactor): Equimolar to Ubc13

  • E3 ligase (e.g., RNF8): Stoichiometric amounts relative to Ubc13

  • Ubiquitin: 25-50 μM

  • ATP: 2-5 mM

  • Buffer: Typically Tris-HCl pH 7.5, 5 mM MgCl₂, 0.1 mM DTT

• Optimize reaction time and temperature:

  • Incubate reactions at 30-37°C

  • Monitor time course from 15 minutes to 2 hours

  • Take multiple timepoints to capture reaction kinetics

• Analyze products by:

  • SDS-PAGE followed by Western blotting with anti-ubiquitin antibodies

  • Use K63-linkage specific antibodies to verify Lys63-linked chain formation

  • Consider native-PAGE for intact chain analysis

• For inhibitor studies:

  • Pre-incubate Ubc13 with inhibitors (e.g., NSC697923 at 1-10 μM) before adding other components

  • Include DMSO-only controls at equivalent concentrations

This methodology provides a robust system for studying Ubc13-mediated Lys63-linked polyubiquitin chain formation and its inhibition.

How can I distinguish between Ubc13-dependent and independent ubiquitination events in cellular systems?

To distinguish between Ubc13-dependent and independent ubiquitination events:

• Create cellular models with controlled Ubc13 activity:

  • Generate Ubc13 knockout (KO) cell lines

  • Complement with wild-type or catalytically inactive Ubc13

  • Use inducible Ubc13 expression systems for temporal control

• Analyze ubiquitin chain linkage types:

  • Use linkage-specific antibodies (K63-specific for Ubc13-dependent events)

  • Employ mass spectrometry to identify and quantify different ubiquitin linkages

  • Compare ubiquitination profiles between wild-type and Ubc13 KO cells

• Implement genetic approaches with Ubc13 inhibitor-resistant mutants:

  • Introduce the Ubc13 QD mutant that remains functional but resists NSC697923 inhibition

  • Compare effects of NSC697923 between cells expressing wild-type versus QD mutant Ubc13

• Analyze downstream signaling events:

  • For DNA damage response: Monitor formation of repair protein foci

  • For NF-κB pathway: Measure nuclear translocation, target gene expression, and cytokine release

This multi-faceted approach provides strong evidence for distinguishing Ubc13-dependent ubiquitination events from those mediated by other E2 enzymes.

What specialized techniques can be used to study the structural basis of Ubc13 inhibition?

To investigate the structural basis of Ubc13 inhibition:

• Apply X-ray crystallography to determine structures of:

  • Ubc13 in complex with inhibitors (e.g., NSC697923, BAY 11-7082)

  • Ubc13 mutants (e.g., the QD mutant) to understand resistance mechanisms

  • Ubc13 in complex with E3 ligase partners to identify potential allosteric effects

• Implement NMR spectroscopy approaches:

  • Perform chemical shift perturbation experiments to map inhibitor binding sites

  • Study dynamics of Ubc13 in solution with and without inhibitors

  • Compare wild-type and mutant Ubc13 dynamics

• Utilize computational methods:

  • Perform molecular dynamics simulations of inhibitor-bound structures

  • Use virtual screening to identify potential new inhibitors targeting the unique Ubc13 binding groove

  • Model the effects of mutations on inhibitor binding

• Apply site-directed mutagenesis to:

  • Create mutations in the unique binding groove near the Ubc13 active site

  • Generate inhibitor-resistant mutants for validation studies

  • Develop Ubc13 variants with altered E3 interaction profiles

These approaches can reveal the molecular details of how inhibitors like NSC697923 exploit the unique binding groove adjacent to the Ubc13 active site, providing insights for rational inhibitor design .

How can I troubleshoot non-specific bands when using UBE2N/Ubc13 antibodies in Western blotting?

When encountering non-specific bands in Western blots with UBE2N/Ubc13 antibodies:

• Optimize blocking conditions:

  • Test different blocking agents (5% non-fat milk, 5% BSA, commercial blockers)

  • Increase blocking time (1-2 hours at room temperature or overnight at 4°C)

  • Add 0.1-0.3% Tween-20 to blocking and washing buffers

• Adjust antibody parameters:

  • Titrate primary antibody concentration (try 1:500 to 1:5000)

  • Reduce incubation time or temperature

  • Perform pre-adsorption with cell lysates from Ubc13 knockout cells

• Improve sample preparation:

  • Include phosphatase inhibitors and deubiquitinase inhibitors in lysis buffers

  • Consider nuclear/cytoplasmic fractionation to enrich for Ubc13

  • Use freshly prepared samples when possible

• Validate with controls:

  • Include lysates from cells overexpressing Ubc13 as positive control

  • Use Ubc13 knockout or knockdown samples as negative control

  • Compare results with a second anti-Ubc13 antibody from a different source

• Modify detection methods:

  • Try alternative secondary antibodies

  • Consider more sensitive detection reagents

  • Adjust exposure times to avoid overexposure

Remember that UBE2N/Ubc13 has a molecular weight of 16 kDa, so bands at this position should represent the specific signal .

What approaches can I use to validate the specificity of Ubc13 inhibitors in cellular systems?

To validate the specificity of Ubc13 inhibitors in cellular systems:

• Generate and utilize the inhibitor-resistant Ubc13 mutant:

  • Introduce the Ubc13 QD mutation that alters the active site loop conformation

  • Verify that the mutant remains enzymatically active in Lys63-linked polyubiquitin chain formation

  • Confirm resistance to NSC697923 using in vitro ubiquitination assays

• Conduct comparative cellular assays:

  • Reintroduce either wild-type Ubc13 or Ubc13 QD into Ubc13 knockout cells

  • Compare inhibitor effects on DNA damage response and NF-κB signaling between these cell lines

  • Quantify pathway-specific readouts such as DNA damage foci or cytokine release profiles

• Perform target validation experiments:

  • Use CRISPR-Cas9 to generate Ubc13 knockout cells

  • Compare inhibitor effects in wild-type versus knockout cells

  • Any effects observed in knockout cells indicate off-target activity

• Analyze structure-activity relationships:

  • Test structurally related compounds with varying potency

  • Correlate biochemical inhibition with cellular effects

  • Identify critical chemical moieties required for Ubc13 inhibition

This multi-layered approach, particularly the use of inhibitor-resistant mutants in cellular assays, provides strong evidence for determining whether observed effects are due to specific Ubc13 inhibition .

How should I interpret contradictory results between antibody-based assays and functional studies of Ubc13?

When facing contradictory results between antibody-based detection and functional studies of Ubc13:

• First, critically examine antibody-based assays:

  • Verify antibody specificity using positive and negative controls

  • Consider epitope accessibility issues in different sample preparations

  • Test alternative antibodies targeting different Ubc13 epitopes

• Assess post-translational modifications:

  • Ubc13 function may be regulated by modifications not detected by all antibodies

  • Use phospho-specific or modification-specific antibodies if available

  • Consider mass spectrometry analysis to identify modifications

• Evaluate protein interactions:

  • Protein complex formation may mask antibody epitopes

  • Interactions with E3 ligases or cofactors like Mms2 may alter antibody recognition

  • Use native versus denaturing conditions to assess complex-dependent effects

• Integrate multiple methodologies:

  • Combine direct antibody detection with activity-based assays

  • Use genetic approaches (siRNA, CRISPR) alongside chemical inhibition

  • Implement the Ubc13 QD mutant system to validate inhibitor specificity

• Consider contextual factors:

  • Cell type-specific differences in Ubc13 regulation

  • Pathway-specific roles in nuclear versus cytoplasmic signaling

  • Stimulus-dependent activation of different Ubc13 functions

By systematically addressing these factors, researchers can reconcile apparently contradictory results and develop a more nuanced understanding of Ubc13 biology.

How can I develop cell-based assays to screen for novel Ubc13 inhibitors?

To develop cell-based assays for screening novel Ubc13 inhibitors:

• Create reporter cell lines:

  • Engineer cells with luciferase reporters downstream of NF-κB response elements

  • Develop fluorescent reporters for DNA damage response pathway activation

  • Generate cell lines expressing fluorescently-tagged Ubc13 substrates

• Design pathway-specific activation protocols:

  • For DNA damage pathway: Use genotoxic agents at standardized doses

  • For NF-κB pathway: Optimize LPS or TNF-α stimulation conditions

• Establish robust readouts:

  • Implement high-content imaging for nuclear translocation or foci formation

  • Develop ELISA-based assays for cytokine release quantification

  • Optimize automated Western blotting for ubiquitination detection

• Include appropriate controls:

  • Use known inhibitors (NSC697923, BAY 11-7082) as positive controls

  • Include Ubc13 knockout cells as reference for complete inhibition

  • Generate cells expressing the Ubc13 QD mutant as specificity controls

• Develop counter-screening assays:

  • Test compounds against related E2 enzymes to assess selectivity

  • Evaluate cytotoxicity profiles to distinguish specific inhibition from general toxicity

  • Measure effects on unrelated cellular pathways

This systematic approach enables the development of physiologically relevant screening systems for identifying novel Ubc13-specific inhibitors with improved selectivity profiles.

What are the considerations for studying Ubc13 in different tissue and disease contexts?

When studying Ubc13 across different tissue and disease contexts:

• Account for tissue-specific expression and regulation:

  • Analyze Ubc13 expression levels across tissues using antibody #4919

  • Consider tissue-specific binding partners and E3 ligases

  • Evaluate tissue-specific post-translational modifications

• Adapt methodologies for different sample types:

  • Optimize protein extraction protocols for specific tissues

  • Adjust antibody dilutions based on Ubc13 abundance in different samples

  • Consider specialized fixation methods for immunohistochemistry

• Incorporate disease-relevant models:

  • For cancer studies: Use patient-derived cell lines and xenografts

  • For inflammatory conditions: Employ appropriate stimuli (e.g., LPS for NF-κB activation)

  • For neurological disorders: Consider brain region-specific analyses

• Implement translational approaches:

  • Correlate Ubc13 activity with disease progression markers

  • Evaluate Ubc13 inhibitor efficacy in disease-relevant primary cells

  • Assess potential biomarkers of Ubc13 activity for patient stratification

• Consider species differences:

  • Verify antibody cross-reactivity with the species being studied (human, mouse, rat, monkey)

  • Account for potential differences in regulatory mechanisms across species

  • Use appropriate species-specific positive controls

These considerations enable researchers to develop more physiologically and clinically relevant models for studying Ubc13 biology in specific disease contexts.

How might advances in understanding Ubc13 structure-function relationships inform future therapeutic development?

The unique structural features of Ubc13 offer promising opportunities for therapeutic development:

• The identification of a distinctive binding groove near the Ubc13 active site provides a structural basis for developing highly specific inhibitors . This groove, not present in many other ubiquitin-conjugating enzymes, could be exploited to create compounds that selectively target Ubc13 while minimizing off-target effects on related E2 enzymes.

• The development of the Ubc13 QD mutant demonstrates that subtle changes in the active site loop conformation can significantly alter inhibitor sensitivity while preserving catalytic function . This insight provides a framework for understanding potential resistance mechanisms and designing next-generation inhibitors that maintain efficacy despite target protein adaptations.

• Differential targeting of Ubc13's roles in specific signaling pathways may allow for more precise therapeutic interventions. By selectively inhibiting Ubc13's function in either DNA damage response or NF-κB signaling, it may be possible to develop pathway-specific modulators with improved therapeutic indices for conditions ranging from inflammatory disorders to cancer.

• The mechanistic understanding of how compounds like NSC697923 and BAY 11-7082 inhibit Ubc13 through covalent adduct formation at the active site cysteine provides a template for rational drug design . Future inhibitors could be engineered to exploit this mechanism while incorporating features that enhance specificity, cell permeability, and pharmacokinetic properties.